Jennison Associates
ORIC icon

Jennison Associates’s Oric Pharmaceuticals ORIC Stock Holding History

Jennison Associates’s Portfolio ORIC Stock Details ORIC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-985,072
Closed -$14.5M – 685
2021
Q4 		$14.5M Sell
985,072
-14,804
-1% -$231K 0.01% 411
2021
Q3 		$20.9M Buy
999,876
+2,931
+0.3% +$59.4K 0.01% 358
2021
Q2 		$17.6M Sell
996,945
-146,534
-13% -$3.21M 0.01% 387
2021
Q1 		$28M Buy
1,143,479
+619,999
+118% +$19.6M 0.02% 307
2020
Q4 		$17.7M Buy
523,480
+372,879
+248% +$10.7M 0.01% 349
2020
Q3 		$3.77M Buy
150,601
+543
+0.4% +$12.9K ﹤0.01% 455
2020
Q2 		$5.06M Buy
+150,058
New +$4.79M ﹤0.01% 429

Other funds holding ORIC

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
CG
Column Group San Francisco, California $101M AUM 290.34% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Jennison Associates's ORIC Position: Q1 2022 in Review

Jennison Associates sold out of Oric Pharmaceuticals (ORIC) in Q1 2022, closing a stake of 985,072 shares — an estimated $14.5M sold.

Jennison Associates first reported a position in ORIC in Q2 2020 and held it in 7 quarters. The position peaked at $28M in Q1 2021. 101 funds tracked by Wall St. Rank hold ORIC as of Q1 2022.

  • Jennison Associates reported no remaining Oric Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Jennison Associates sold 985,072 Oric Pharmaceuticals shares in Q1 2022, an estimated $14.5M.
  • Jennison Associates first reported a position in Oric Pharmaceuticals in Q2 2020 and held it in 7 quarters.
  • Jennison Associates's Oric Pharmaceuticals position peaked at $28M in Q1 2021.
  • 101 funds tracked by Wall St. Rank held Oric Pharmaceuticals as of Q1 2022.

Based on Jennison Associates's 13F filing for Q1 2022, filed 11 May 2022.